Stromal Hedgehog Signaling Is Associated with Favorable Outcomes in Pancreatic Cancer
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26115200 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Paul Manoukian und 4 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Experimental Oncology and Radiobiology, Cancer Center Amsterdam, Amsterdam UMC and University of Amsterdam, 1081 BT Amsterdam, The Neth…. Hauptthemen laut MEDLINE: Hedgehog Proteins, Pancreatic Neoplasms, Signal Transduction, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dutch Cancer Society, H2020-MSCA-ITN, KWF project.
Abstract (Originalsprache)
Aberrant activation of the Hedgehog (Hh) signaling pathway can be observed in various malignancies, particularly in stroma-rich tumors like pancreatic ductal adenocarcinoma (PDAC). In PDAC, Hh signaling is thought to foster an abundant stroma, making it an appealing target for stoma-targeted therapy. However, the use of Hh antagonists in the clinic has thus far not been successful. To reassess the clinical merit of Hh-targeted therapy in PDAC, we sought to better characterize the role of Hh signaling in tumor-stroma crosstalk. Here, we show that Hh ligands are not prognostic per se in PDAC, despite being associated with the favorable classical molecular subtype. Perturbing Hh ligand expression in PDAC cells can effectively alter their trans-signaling capacity but does not impact tumor growth in vivo. However, co-injecting PDAC cells with Smo-proficient MEFs resulted in a significant reduction in xenograft growth, suggesting that Hh-related effects on tumor growth are largely mediated through the stroma. By analyzing transcriptomic sequencing data from co-cultures, comprising human PDAC cells and mouse fibroblasts treated with a Hh-blocking antibody, we could identify stromal hits that are responsive to Hh ligands. We then leveraged the obtained set of genes to allow patient stratification based on stromal response to Hh ligands. We believe that a subset of PDAC patients may benefit from the use of Hh-targeted therapies and thereby encourage the use of our stratification tool to guide their use in PDAC clinical care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Experimental Oncology and Radiobiology, Cancer Center Amsterdam, Amsterdam UMC and University of Amsterdam, 1081 BT Amsterdam, The Netherlands.
- Cancer Center Amsterdam, Cancer Biology, 1081 BT Amsterdam, The Netherlands.
- BiOrigin, 2200 Copenhagen, Denmark.
- Department of Medicine, Stanford University School of Medicine, Palo Alto, CA 94305, USA.
- Department of Medical Oncology, Amsterdam UMC and University of Amsterdam, 1081 HV Amsterdam, The Netherlands.
ORCID-Profile: Helene Damhofer, Hanneke W M van Laarhoven, Maarten F Bijlsma
Förderung
- Dutch Cancer Society
- H2020-MSCA-ITN
- KWF project
Zitieren
APA
Manoukian, P., Damhofer, H., Zhao, L., van Laarhoven, H. W. M., & Bijlsma, M. F. (2025). Stromal Hedgehog Signaling Is Associated with Favorable Outcomes in Pancreatic Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26115200
Vancouver
Manoukian P, Damhofer H, Zhao L, van Laarhoven HWM, Bijlsma MF. Stromal Hedgehog Signaling Is Associated with Favorable Outcomes in Pancreatic Cancer. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26115200
BibTeX
@article{Manoukian2025,
author = {Manoukian, Paul and Damhofer, Helene and Zhao, Lan and van Laarhoven, Hanneke W M and Bijlsma, Maarten F},
title = {Stromal Hedgehog Signaling Is Associated with Favorable Outcomes in Pancreatic Cancer},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26115200}
}
EUVIMED